Potentiation of response to insulin and anti-insulin action by two human pituitary peptides in lean agouti A/a, obese yellow Avy/A, and C57BL/6J-ob/ob mice.
Insulin-like and anti-insulin effects of human growth hormone (hGH) were examined by determining the effects of two peptides representing portions of the hGH molecule in lean agouti A/a and obese yellow Avy/A and ob/ob mice. The peptides were the amino terminal segment, residue 1-43 (hGH1-43), which has been shown to potentiate the response to insulin and another peptide, hyperglycemic peptide (HP), with unknown structure, which has anti-insulin activity. The anti-insulin component is an acidic low molecular weight peptide which co-purifies with hGH but was not recognized by antibodies to intact hGH and did not cross-react with anti-hGH1-43 antiserum. The purpose of these studies was to further understand the multiple actions of hGH and its acute and chronic effects on response to insulin. Injections of hGH1-43 dramatically enhanced the effect of insulin on glucose clearance of obese yellow Avy/A and ob/ob mice and increased the insulin-stimulated glucose oxidation in adipose tissue of yellow mice, but had no direct effect on blood glucose or insulin levels of either genotype. Administration of HP to obese yellow mice produced hyperglycemia and suppressed serum insulin concentrations. Tissues from lean agouti and obese yellow mice treated with HP in vitro showed decreased basal and insulin-stimulated glucose oxidation as well as decreased 14C incorporation into lipids. Chronic treatment of obese yellow and ob/ob mice with HP increased fasting blood glucose and impaired glucose tolerance. The effect of HP was more pronounced in obese yellow mice and the ob/ob mice were more sensitive to the diabetogenic actions of intact hGH. These data provide further evidence for the existence of two opposing biologic activities derived from disparate amino acid sequences in hGH. Additionally, the data indicate that assays using obese yellow Avy/A mice can distinguish the effects of hGH from those of the individual peptides to a greater degree than assays using obese ob/ob mice.
Salem
M A
MA
Lutcher Brown Department of Biochemistry, Whittier Institute for Diabetes and Endocrinology, Scripps Memorial Hospital, La Jolla, California 92037.
Wolff
G L
GL
D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004357:Drug Synergism; D005260:Female; D005947:Glucose / Q000378:metabolism; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000494:pharmacology*; D019382:Human Growth Hormone; D007328:Insulin / Q000097:blood / Q000494:pharmacology*; D007329:Insulin Antagonists / Q000494:pharmacology*; D051379:Mice; D008817:Mice, Mutant Strains / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology*; D010907:Pituitary Hormones / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D007329:Insulin Antagonists; D010446:Peptide Fragments; D010907:Pituitary Hormones; C010912:diabetogenic factor, human; C039519:somatotropin 20K; D019382:Human Growth Hormone; C056878:somatotropin (1-43); D013006:Growth Hormone; D005947:Glucose